Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804955 | 0.83 | DHFR (0.38) | ALDH1A1DHFRABL1S1PR1NOTUM | |
| SCHEMBL15417759 | 0.80 | NOS3 (0.44) | ALDH1A1DHFRABL1NOS3NOS1 | |
| SCHEMBL28266208 | 0.80 | ALDH1A1 (0.38) | ALDH1A1S1PR1NOTUM | |
| SCHEMBL22978563 | 0.77 | NOS2 (0.42) | NOS2 | |
| SCHEMBL13343541 | 0.77 | ALDH1A1 (0.36) | ALDH1A1DHFRABL1NOS3NOS1 | |
| SCHEMBL14224045 | 0.75 | UHRF1 (0.54) | ALDH1A1DHFRABL1NOS3NOS1 | |
| SCHEMBL17316728 | 0.75 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL5498305 | 0.75 | DHFR (0.43) | ALDH1A1DHFRABL1NOS3NOS1 | |
| SCHEMBL19171832 | 0.75 | UHRF1 (0.43) | ALDH1A1DHFRABL1NOS3NOS1 | |
| SCHEMBL15273816 | 0.75 | HSD17B10 (0.42) | ALDH1A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001273-B | Pyridine derivatives | 安斯泰来制药株式会社 | 2020-05-12 | — | — | CN | disclosed |
| EP-3228616-B1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-10005762-B2 | Pyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170362209-A1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3228616-A1 | PYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| CN-100378072-C | Heterocyclic methyl sulfone derivative | DAIICHI SEIYAKU CO (JP) | 2008-04-02 | — | — | CN | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1640366-A1 | HETEROCYCLIC METHYL SULFONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | ALDH1A1 3313/4885DHFR 2463/4885ABL1 3362/4885 |
| US-10005762-B2 | Pyridine derivatives | LAP3, PREP, DNPEP | ALDH1A1 240/4885DHFR 1878/4885ABL1 4112/4885 |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | XDH, CYP2B6, COX6B1 | ALDH1A1 1279/4885DHFR 579/4885ABL1 546/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ALDH1A1 1279/4885DHFR 579/4885ABL1 546/4885 |
| US-20170362209-A1 | PYRIDINE DERIVATIVES | LAP3, PREP, DNPEP | ALDH1A1 240/4885DHFR 1878/4885ABL1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.